Skip to main navigation Skip to search Skip to main content

CN012-0052: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer's Disease

Project: Research

Project Details

StatusActive
Effective start/end date10/6/25 → 04/1/28

Funding

  • Bristol Myers Squibb Company: $65,185.40